---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-026086"
form_type: "8-K"
ticker: "KURA"
cik: "0001422143"
company_name: "Kura Oncology, Inc."
filed_at: "2023-06-02T23:59:59+00:00"
generated_at: "2026-06-14T08:06:22.398161+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Stockholders approve amendment increasing share reserve by 4.05M shares

## Summary
- At May 31 annual meeting, stockholders approved Amended 2014 Plan increasing authorized shares by 4,050,000.
- Diane Parks and Mary T. Szela elected as Class III directors until 2026 annual meeting.
- Ernst & Young LLP ratified as independent auditor for fiscal year ending Dec 31, 2023.
- Advisory vote on executive compensation approved with ~52M for vs ~0.88M against.
- Amended 2014 Plan approved with ~46.8M for, ~5.9M against, ~1.4M abstain.

## SEC filing metadata
- accession: 0000950170-23-026086
- form_type: 8-K
- ticker: KURA
- cik: 0001422143
- company_name: Kura Oncology, Inc.
- filed_at: 2023-06-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422143/000095017023026086/0000950170-23-026086-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422143/000095017023026086/kura-20230531.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-026086
- JSON: https://secwatch.observer/filing/0000950170-23-026086.json
- Plain text: https://secwatch.observer/filing/0000950170-23-026086.txt

## Key facts
- Shareholder Votes
  Kura Oncology, Inc. shareholders approved Election of Class III Directors at the 2023-05-31 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-05-31
  source text: Name of Director Elected For Withheld Broker Non-Votes Diane Parks 39,370,803 14,742,373 1,860,281 Mary T. Szela 53,945,761 167,415 1,860,281
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422143/000095017023026086/0000950170-23-026086-index.htm
- Shareholder Votes
  Kura Oncology, Inc. shareholders approved Ratification of Appointment of Ernst & Young LLP as Independent Registered Public Accounting Firm at the 2023-05-31 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-05-31
  source text: For Against Abstain Broker Non-Votes 55,916,556 34,565 22,336 —
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422143/000095017023026086/0000950170-23-026086-index.htm
- Shareholder Votes
  Kura Oncology, Inc. shareholders approved Approval of Amended 2014 Plan at the 2023-05-31 meeting.
  - Proposal: equity plan
  - Outcome: passed
  - Meeting: 2023-05-31
  source text: For Against Abstain Broker Non-Votes 46,803,922 5,914,387 1,394,867 1,860,281
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422143/000095017023026086/0000950170-23-026086-index.htm
- Shareholder Votes
  Kura Oncology, Inc. shareholders approved Advisory Vote on Executive Compensation at the 2023-05-31 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-05-31
  source text: For Against Abstain Broker Non-Votes 51,834,962 879,497 1,398,717 1,860,281
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422143/000095017023026086/0000950170-23-026086-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.